📄 pharmacology and therapeutics

Real-world safety profile of Enfortumab Vedotin: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS)

This comprehensive pharmacovigilance analysis of the FAERS database confirms known safety risks of Enfortumab Vedotin while identifying new adverse event signals and demographic-specific toxicity patterns, highlighting the critical need for proactive monitoring during the first two weeks of treatment.

Original authors: Xu, Q., Wang, S., Sun, H., Wei, X., Zhong, J., Cai, J.

Published 2026-06-09

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Xu, Q., Wang, S., Sun, H., Wei, X., Zhong, J., Cai, J.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine Enfortumab Vedotin (EV) as a highly specialized "smart missile" designed to hunt down bladder cancer cells. It works by latching onto a specific target on the cancer cells, entering them, and releasing a toxic payload that stops the cancer from growing. While this weapon is powerful and has changed how doctors treat advanced bladder cancer, like any powerful tool, it can sometimes hit the wrong targets or cause collateral damage to the healthy body.

This paper is essentially a massive safety audit of that "smart missile" after it has been used in the real world, rather than just in controlled laboratory trials. The researchers acted like detectives, sifting through a giant database called FAERS (the FDA's "complaint box" where doctors and patients report side effects) to find patterns in how the drug behaves in millions of people.

Here is the breakdown of their findings using simple analogies:

1. The Detective Work: How They Found the Clues

Instead of just looking at a few cases, the researchers used four different mathematical "flashlights" (statistical algorithms) to scan over 11 million reports. They were looking for signals that stood out—like finding a specific type of noise in a crowded room. By using four different methods, they made sure they weren't just seeing ghosts (false alarms) but were catching real safety signals.

2. The Main Culprits: Where the "Missile" Hits

The study confirmed what doctors already knew, but with more precision:

The Skin is the Most Common Target: Just as a missile might scorch the ground it lands on, the drug causes the most trouble with the skin and tissues under the skin. About 18% of all reported issues were skin-related (rashes, itching, blisters).
The Nerves and Metabolism: The drug also frequently trips up the nervous system (causing numbness or tingling in hands and feet) and the metabolism (causing high blood sugar).

3. New Clues: Things We Didn't Expect

The most exciting part of the study is that they found new "footprints" that weren't fully highlighted in the original drug instructions:

Taste Buds: Many patients reported dysgeusia (a weird or metallic taste in the mouth). It's like the drug is confusing the taste sensors, making food taste "off."
Bone Marrow: There were signals for myelosuppression, meaning the drug might be slowing down the factory that makes blood cells.
Atypical Skin Lesions: The study found many reports of strange skin spots that didn't fit standard categories. The researchers warn that these could be the "early warning smoke" before a serious fire (severe skin reactions) starts.

4. The Timing: The "Early Failure" Pattern

If you imagine the drug's side effects as a ticking clock, this study found that the clock ticks loudest immediately.

The First Two Weeks: The "median time to onset" was just 14 days. This means half of all the bad reactions happened within the first two weeks of starting treatment.
The Analogy: Think of it like a car with a "break-in" period. If the car is going to have a major mechanical failure, it usually happens right after you start driving it, not after a year. The risk of side effects drops off significantly after that first month.

5. Who is Most at Risk? (The Demographic Map)

The study found that different groups of people react differently, like how different car models handle rough roads differently:

Older Adults (65+) and Women: These groups are like "sensitive sensors." They are more prone to severe skin reactions that can be life-threatening (like Stevens-Johnson syndrome). The study suggests they need extra vigilance for skin issues.
Younger Adults and Men: These groups are more like "heavy-duty engines" that might overheat in different ways. They showed higher susceptibility to neurological issues (nerve damage) and metabolic issues (blood sugar problems).

6. The Bottom Line

This paper doesn't tell us to stop using the drug; rather, it acts as a detailed user manual update. It tells doctors:

Watch the clock: Pay the most attention during the first two weeks.
Know your patient: Be extra careful with skin checks for older women, and keep a closer eye on nerves and blood sugar for younger men.
Listen to the new signals: Don't ignore weird tastes or unexplained skin spots, as they could be early warnings of bigger problems.

In short, the study confirms the drug is effective but highlights that its "side effects" have a specific personality: they strike early, they target the skin and nerves, and they affect different people in different ways.

Technical Summary: Real-world Safety Profile of Enfortumab Vedotin

Problem Statement
Enfortumab Vedotin (EV), an antibody-drug conjugate (ADC) targeting Nectin-4, has emerged as a preferred first-line standard of care for locally advanced or metastatic urothelial carcinoma (la/mUC), largely due to its superior overall survival outcomes compared to traditional platinum-based chemotherapy. However, pre-marketing clinical trials are often constrained by limited sample sizes, strict eligibility criteria, and short follow-up periods, potentially overlooking rare or long-term adverse events (AEs). While EV is known to cause specific toxicities such as rash and peripheral neuropathy, a comprehensive understanding of its real-world safety profile, including the identification of potential new risks, the temporal onset of events, and demographic-specific vulnerabilities, remains necessary to optimize clinical risk management.

Methodology
This study conducted a comprehensive pharmacovigilance analysis using data from the FDA Adverse Event Reporting System (FAERS) covering the period from the first quarter of 2019 to the third quarter of 2025.

Data Processing: From over 11.6 million reports, the study isolated 14,511 reports where EV was the primary suspect, involving 4,177 unique patients. Rigorous deduplication procedures were applied based on FDA guidelines.
Signal Detection: To ensure robustness and minimize false positives, the study employed a multi-algorithm consensus approach using four disproportionality analysis methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayes Geometric Mean (EBGM). Only signals meeting the positive thresholds of all four algorithms were considered.
Data Cleaning: To isolate drug-specific signals, terms related to the underlying disease (urothelial carcinoma) and non-drug-related events were strictly excluded.
Temporal and Subgroup Analysis: The Time to Onset (TTO) was analyzed using a Weibull distribution model to characterize the failure pattern. Furthermore, stratified subgroup analyses were performed based on sex, age (<65 vs. ≥65 years), and severity (serious vs. non-serious) to identify heterogeneity in toxicity profiles.

Key Results

Adverse Event Burden: The most frequently reported System Organ Classes (SOCs) were skin and subcutaneous tissue disorders (18.23%) and general disorders/administration site conditions (13.17%).
Signal Identification: The analysis identified 179 positive signals. While confirming known toxicities such as peripheral neuropathy, hyperglycemia, and rash, the study highlighted potential new or under-recognized signals, including dysgeusia (taste disorder), atypical skin lesions, and myelosuppression.
Temporal Profile: The median TTO was 14 days (IQR: 7–45 days). The Weibull shape parameter ( $\beta$ ) was 0.736 (95% CI: 0.711–0.762), indicating an "early failure" profile where the risk of AEs is highest immediately after initiation and decreases over time. The majority of events occurred within the first two weeks.
Demographic Heterogeneity:
- Sex: Female patients exhibited stronger signals for severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Male patients showed higher susceptibility to metabolic toxicities (e.g., hyperglycemia) and certain neurological effects.
- Age: Patients aged ≥65 years demonstrated significantly stronger signals for severe skin toxicities compared to younger patients. Conversely, patients aged <65 years showed higher susceptibility to neurological and sensory toxicities, such as peripheral neuropathy and dysgeusia.
- Severity: The vast majority of reports (85.47%) were classified as serious. While mathematical artifacts in spontaneous reporting systems can inflate RORs for rare events in non-serious categories, the absolute burden of SCARs was concentrated in the serious subgroup.

Significance and Claims
The authors claim that this study provides a robust, data-driven validation of EV's safety profile in a real-world setting, extending beyond the limitations of randomized controlled trials. By utilizing a quadruple-algorithm approach, the study effectively filters noise to identify high-confidence safety signals.

The primary significance of the findings lies in the identification of specific risk stratification strategies:

Timing: The "early failure" profile underscores the critical importance of proactive monitoring during the first two weeks of treatment, particularly for the first two cycles.
Personalized Monitoring: The study advocates for demographic-specific vigilance. Clinicians should prioritize monitoring for fatal skin toxicity in elderly and female patients, while maintaining close follow-up of neurological and metabolic indicators in younger and male populations.
New Risk Awareness: The identification of dysgeusia and the warning regarding atypical skin lesions as potential prodromal symptoms of severe reactions offers actionable insights for early intervention, potentially preventing irreversible adverse outcomes.

The authors conclude that these insights provide a scientific basis for optimizing EV risk management, enabling clinicians to implement individualized monitoring strategies to enhance patient safety. The study acknowledges inherent limitations of spontaneous reporting systems, such as underreporting and the inability to establish causality, but asserts that the cross-validated signal detection offers valuable early warnings for clinical practice.